

Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.
Phone: +91- 2717-430479 | +91- 2717-410819
e-mail: info@arveelabs.com, Website: www.arveelabs.com
CIN No. :- L24231GJ2012PLC068778.



Date: 14th February, 2022

**To,
National Stock Exchange of India Limited
Mumbai**

Scrip Code: ARVEE

Dear Sir/Ma'am,

Subject: Newspaper Publication of Results

With reference to the above subject kindly find enclosed herewith the quarterly results published in newspaper in English and Gujarati newspaper.

You are requested to take same on your record.

Thanking you,

Yours Faithfully,

For, Arvee Laboratories (India) Limited

S. Gandhi
Saurin Gandhi
Chief Financial Officer



FINANCIAL EXPRESS

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road, Ambli, Ahmedabad, Gujarat 380058
Telephone: +91-2717-430479 / +91-2717-410819, Website : www.arveelabs.com
CIN : L24231GJ2012PLC068778 Email : compliance@arveelabs.com

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON DECEMBER 31, 2021 (₹ in lakhs except per share data)

Sr. No.	Particular	Quarter ended			Nine Month ended		Year ended
		31-12-2021 (Un Audited)	30-09-2021 (Un Audited)	31-12-2020 (Un Audited)	31-12-2021 (Un Audited)	31-12-2020 (Un Audited)	31-03-2021 (Audited)
1.	Total Revenue from operations	790.06	1069.98	1994.48	2766.23	3818.53	4737.50
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	66.73	103.84	204.45	241.18	301.26	364.14
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	66.73	103.84	204.45	241.18	301.26	364.14
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	53.39	72.59	152.99	178.82	224.30	267.74
5.	Total Comprehensive Income for the period	53.39	72.59	152.99	178.82	224.30	267.74
6.	Paid up Equity Share Capital (Face value of Rs.10/- each)	1102.00	1102.00	1102.00	1102.00	1102.00	1102.00
7.	Other Equity excluding revaluation reserves						1041.82
8.	Earnings Per Share (of Rs.10/- each) (Not Annualised) (for continuing & discontinued operations)						
	a) Basic	0.48	0.66	1.39	1.62	4.07	2.43
	b) Diluted	0.48	0.66	1.39	1.62	4.07	2.43

Notes:

- The above is an extract of the detailed format of Financial Results for the quarter ended December 31, 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the said Results are available on the Stock Exchange website (www.nseindia.com) and on the Company's website (www.arveelabs.com).
- In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the Company fall under the Chemicals business which is considered to be the only reportable segment by the management.

For, Arvee Laboratories (India) Limited
S/d

Place : Ahmedabad

Date : February 08, 2022

SHALIN SUDHAKARBHAI PATEL
Chairman & Managing Director



Regd. Office: Baroda - Godhra Highway, Kalol, District Panchmahal, Pin Code - 389 330, Gujarat. • Tel: 02676 - 270600 • Fax: 02676 - 235524
Website: www.setcoauto.com • Email: investor.relations@setcoauto.com
CIN.: U35100GJ2010PTC062770

Extract of Standalone Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2021

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-21 (Unaudited)	30-Sep-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Mar-21 (Audited)
1	Total Income from Operations	10,254	2,283	-	12,537	-	-
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(3,132)	(1,954)	-	(5,086)	-	-
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(3,132)	(12,730)	-	(15,862)	-	-
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(3,132)	(12,730)	-	(15,862)	-	-
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(3,132)	(12,730)	-	(15,862)	-	-
6	Paid-up Equity Share Capital (F.V. of Rs. 10/- each)	87	87	-	87	-	1
7	Reserves (excluding Revaluation Reserve) *	(24,127)	(20,995)	-	(24,127)	-	(3)
8	Securities Premium Account	4,962	4,962	-	4,962	-	-
9	Net worth	(24,040)	(20,907)	-	(24,040)	-	(2)
10	Paid up Debt Capital/ Outstanding Debt	56,522	56,522	-	56,522	-	-
11	Outstanding Redeemable Preference Shares	-	-	-	-	-	-
12	Debt Equity Ratio	(2.60)	(2.85)	-	(2.60)	-	(0.47)
13	Earnings Per Share (F.V. of ₹ 10/- each)						
	Basic	(549.11)	(3,046.60)	-	(2,780.86)	-	(1.50)
	Diluted	(472.74)	(2,851.10)	-	(2,394.07)	-	(1.50)
14	Capital Redemption Reserve	-	-	-	-	-	-
15	Debenture Redemption Reserve	-	-	-	-	-	-
16	Debt Service Coverage Ratio	0.004	(1.06)	-	(0.27)	-	-

LIMITED
 Ahmedabad - 380 009
 dated 31/12/2021
 (laks except EPS)
 Corresponding
 Three Months
 Ended in the
 Previous Year
 31.12.2020
 0.56
 0.05
 0.05
 0.05
 0.05
 385.04
 -
 10/-
 0.00
 al Results filed
 R) Regulations,
 le on the Stock
 rize Limited
 SD/-
 mar Malviya
 ging Director
 N: 08015437

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon Bopal Road, Ambli, Ahmedabad, Gujarat 380058
 Telephone: +91-2717-430479 / +91-2717-410819, Website: www.arveelabs.com
 CIN : L24231GJ2012PLC068778 Email : compliance@arveelabs.com

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON DECEMBER 31, 2021 (₹ in lakhs except per share)

Sr. No.	Particular	Quarter ended			Nine Month ended	
		31-12-2021 (Un Audited)	30-09-2021 (Un Audited)	31-12-2020 (Un Audited)	31-12-2021 (Un Audited)	31-12-2020 (Un Audited)
1.	Total Revenue from operations	790.06	1069.98	1994.48	2766.23	3818.53
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	66.73	103.84	204.45	241.18	301.26
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	66.73	103.84	204.45	241.18	301.26
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	53.39	72.59	152.99	178.82	224.30
5.	Total Comprehensive Income for the period	53.39	72.59	152.99	178.82	224.30
6.	Paid up Equity Share Capital (Face value of Rs.10/- each)	1102.00	1102.00	1102.00	1102.00	1102.00
7.	Other Equity excluding revaluation reserves					
8.	Earnings Per Share (of Rs.10/- each) (Not Annualised) (for continuing & discontinued operations)					
	a) Basic	0.48	0.66	1.39	1.62	4.07
	b) Diluted	0.48	0.66	1.39	1.62	4.07

Notes:

- The above is an extract of the detailed format of Financial Results for the quarter ended December 31, 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the said Results are available on the Stock Exchange website (www.nseindia.com) and on the Company's website (www.arveelabs.com).
- In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the Company are reported under the Chemicals business which is considered to be the only reportable segment by the management.

For, Arvee Laboratories (India) Limited

Place : Ahmedabad
 Date : February 08, 2022

SHALIN SUDHAKAR
 Chairman & Managing Director

This is only an advertisement for information purposes and is not a prospectus announcement.



VAIDYA SANE AYURVED LABORATORIES LIMITED

Corporate Identification Number: U73100PN1999PLC013509

Company under the Companies Act, 1956 pursuant to a certificate of incorporation issued by the Registrar of Companies, Pune dated April 6, 1999 with the name 'Vaidya Sane Ayurved Laboratories Limited' and the name of our Company was changed to 'Vaidya Sane Ayurved Laboratories Limited' by a special resolution passed on November 19, 2021. A fresh Certificate of Incorporation was issued by the Registrar of Companies, Pune. For further details of our Company, see "General Information" and "History and Certain Other Corporate Matters" on pages 41 and 93, respectively of the Prospectus.
 Office Address where books of account and papers are maintained: 201 B, Bhoomi Velocity, Road No. 23, Above ICICI Bank, Vastani, Pune - 411002, Maharashtra, India; Tel: +91 7738070019; Website: www.madhavbaug.org; E-mail: cs@madhavbaug.com; Contact Person: Abhishek Ajay Deshpande, Company Secretary

PROMOTER OF THE COMPANY: DR. ROHIT MADHAV SANE

THE ISSUE

ISSUE OF FACE VALUE OF ₹ 10.00 EACH OF VAIDYA SANE AYURVED LABORATORIES LIMITED ("OUR COMPANY" OR "THE ISSUING COMPANY") EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 63.00 PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO ₹ 2,00,00,000. OUT OF WHICH ₹ 10,00,000 (5% OF THE TOTAL ISSUE) WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 26,30,400 EQUITY SHARES OF FACE VALUE ₹ 10.00 PER EQUITY SHARE AGGREGATING TO ₹ 1920.19 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUING COMPANY HAS RESERVED 10% OF THE NET ISSUE, THAT IS, ₹ 192.019 LAKHS AND 25.02%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS OF THE PROSPECTUS.